Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Histopathology
    July 2024
  1. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
    Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
    Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
    >> Share

  2. TOZBIKIAN G, Bui MM, Hicks DG, Jaffer S, et al
    Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.
    Histopathology. 2024 Jul 8. doi: 10.1111/his.15275.
    >> Share

  3. ZHANG H, Finkelman BS, Ettel MG, Velez MJ, et al
    HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
    Histopathology. 2024;85:3-19.
    >> Share

    June 2024
  4. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    >> Share

  5. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    >> Share

  6. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    >> Share

  7. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    >> Share

    May 2024
  8. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    >> Share

  9. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    >> Share

    April 2024
  10. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    >> Share

  11. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    >> Share

  12. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    >> Share

  13. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    >> Share

    March 2024
  14. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    >> Share

    January 2024
  15. LUI JW, Tsang JY, Li J, Ko CW, et al
    TRPS1 is a promising marker for all subtypes of breast cancer.
    Histopathology. 2024 Jan 3. doi: 10.1111/his.15126.
    >> Share

  16. SCHWARTZ CJ, Krings G, Chen YY
    Malignant phyllodes tumour with lymph node metastasis: a diagnostic conundrum resolved by next generation DNA sequencing.
    Histopathology. 2024;84:409-411.
    >> Share

    December 2023
  17. TAN PH, Mihir G, Laokulrath N, Rakha E, et al
    Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines.
    Histopathology. 2023 Dec 12. doi: 10.1111/his.15117.
    >> Share

  18. BOYRAZ B, Sgroi DC, Iafrate AJ, Lerwill MF, et al
    Atypical cystic hypersecretory lesions of the breast commonly harbour TP53 alterations.
    Histopathology. 2023;83:989-993.
    >> Share

    September 2023
  19. LEE AHS, Toss MS, James JJ, Hodi Z, et al
    Preoperative diagnosis of ductal carcinoma in situ of the breast over a 24-year period.
    Histopathology. 2023;83:435-442.
    >> Share

  20. RAKHA EA, Adebayo LA, Abbas A, Hodi Z, et al
    Second opinion (external specialist referral) practice of breast pathology: the Nottingham experience.
    Histopathology. 2023;83:394-405.
    >> Share

  21. GHANNAM SF, Rutland CS, Allegrucci C, Mongan NP, et al
    Encapsulated papillary carcinoma of the breast: does it have a native basement membrane?
    Histopathology. 2023;83:376-393.
    >> Share

  22. AIYER KTS, Kroon LJ, van Leenders GJLH
    Impact of comedonecrosis on prostate cancer outcome: a systematic review.
    Histopathology. 2023;83:339-347.
    >> Share

  23. JORNS JM, Farooq A, Puzyrenko A, Jarzembowski J, et al
    Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)-like change: clinicopathological and molecular characteristics.
    Histopathology. 2023;83:357-365.
    >> Share

    August 2023
  24. NIELSEN TO, Leung SCY, Riaz N, Mulligan AM, et al
    Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial.
    Histopathology. 2023 Aug 23. doi: 10.1111/his.15032.
    >> Share

  25. LEWIS G, Fong N, Gjeorgjievski SG, Li XB, et al
    Low-grade adenosquamous carcinoma of the breast: a clinical, morphological and immunohistochemical analysis of 25 patients.
    Histopathology. 2023;83:252-263.
    >> Share

    July 2023
  26. THORNE H, Devereux L, Li J, Alsop K, et al
    BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
    Histopathology. 2023;83:91-103.
    >> Share

    June 2023
  27. GOUGH M, Liu C, Srinivasan B, Wilkinson L, et al
    Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer.
    Histopathology. 2023 Jun 27. doi: 10.1111/his.15000.
    >> Share

    May 2023
  28. HARTER D, O'Connor SM, Hertel JD, Calhoun BC, et al
    Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy.
    Histopathology. 2023 May 31. doi: 10.1111/his.14966.
    >> Share

  29. LASHEN AG, Toss MS, Wootton L, Green AR, et al
    Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer.
    Histopathology. 2023 May 24. doi: 10.1111/his.14960.
    >> Share

    April 2023
  30. ZENG L, Koh VCY, Chen XY, Tan PH, et al
    Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters.
    Histopathology. 2023;82:779-788.
    >> Share

  31. LASHEN A, Toss MS, Fadhil W, Oni G, et al
    Evaluation oncotype DX((R)) 21-gene recurrence score and clinicopathological parameters: a single institutional experience.
    Histopathology. 2023;82:755-766.
    >> Share

  32. MD NASIR ND, Koh VCY, Cree IA, Ruiz BII, et al
    Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast.
    Histopathology. 2023;82:704-712.
    >> Share

  33. CHARTIER S, Brochard C, Martinat C, Coussy F, et al
    TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.
    Histopathology. 2023;82:664-671.
    >> Share

    February 2023
  34. IBRAHIM A, Toss MS, Atallah NM, Al Saleem M, et al
    Combined proliferation and apoptosis index provides better risk stratification in breast cancer.
    Histopathology. 2023 Feb 13. doi: 10.1111/his.14887.
    >> Share

  35. SODE M, Thagaard J, Eriksen JO, Laenkholm AV, et al
    Digital image analysis and assisted reading of the HER2 score display reduced concordance - Pitfalls in the categorization of HER2-low breast cancer.
    Histopathology. 2023 Feb 3. doi: 10.1111/his.14877.
    >> Share

  36. LAI BS, Tsang JY, Li JJ, Poon IK, et al
    Anatomical site and size of sentinel lymph node metastasis predicted additional axillary tumour burden and breast cancer survival.
    Histopathology. 2023 Feb 1. doi: 10.1111/his.14875.
    >> Share

    January 2023
  37. ELLIS IO, Rakha EA, Tse GM, Tan PH, et al
    An international unified approach to reporting and grading invasive breast cancer. An overview of the International Collaboration on Cancer Reporting (ICCR) initiative.
    Histopathology. 2023;82:189-197.
    >> Share

  38. RAKHA EA, Tse GM, Quinn CM
    An update on the pathological classification of breast cancer.
    Histopathology. 2023;82:5-16.
    >> Share

  39. CHAN RC, To CKC, Cheng KCT, Yoshikazu T, et al
    Artificial intelligence in breast cancer histopathology.
    Histopathology. 2023;82:198-210.
    >> Share

  40. PROVENZANO E, Shaaban AM
    Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer.
    Histopathology. 2023;82:170-188.
    >> Share

  41. SOKOLOVA A, Johnstone KJ, McCart Reed AE, Simpson PT, et al
    Hereditary breast cancer: syndromes, tumour pathology and molecular testing.
    Histopathology. 2023;82:70-82.
    >> Share

  42. NOURIEH M, Vibert R, Saint-Ghislain M, Cyrta J, et al
    Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.
    Histopathology. 2023;82:162-169.
    >> Share

  43. TAN BY, Fox SB, Lakhani SR, Tan PH, et al
    Survey of recurrent diagnostic challenges in breast phyllodes tumours.
    Histopathology. 2023;82:95-105.
    >> Share

  44. TSANG JY, Tse GM
    Update on triple-negative breast cancers - highlighting subtyping update and treatment implication.
    Histopathology. 2023;82:17-35.
    >> Share

  45. LI JJX, Tse GM
    Marker assessments in ER-positive breast cancers: old markers, new applications?
    Histopathology. 2023;82:218-231.
    >> Share

    November 2022
  46. IBRAHIM A, Toss MS, Makhlouf S, Miligy IM, et al
    Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
    Histopathology. 2022 Nov 8. doi: 10.1111/his.14837.
    >> Share

  47. XU B, Viswanathan K, Umrau K, Al-Ameri TAD, et al
    Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors.
    Histopathology. 2022;81:670-679.
    >> Share

    October 2022
  48. FOX SB, Webster F, Chen CJ, Chua B, et al
    Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2022;81:467-476.
    >> Share

    September 2022
  49. VERNEMMEN AIP, Li X, Roemen GMJM, Speel EM, et al
    Cutaneous metastases of internal malignancies: a single-institution experience.
    Histopathology. 2022;81:329-341.
    >> Share

    August 2022
  50. ATALLAH NM, Toss MS, Green AR, Mongan NP, et al
    Refining the definition of HER2 low class in invasive breast cancer.
    Histopathology. 2022 Aug 28. doi: 10.1111/his.14780.
    >> Share

  51. LASHEN A, Toss MS, Green AR, Mongan NP, et al
    Ki67 assessment in invasive luminal breast cancer: A comparative study between different scoring methods.
    Histopathology. 2022 Aug 23. doi: 10.1111/his.14781.
    >> Share

  52. OISHI N, Feldman AL
    CA9 expression in breast implant-associated anaplastic large cell lymphoma presenting in a lymph node.
    Histopathology. 2022;81:270-272.
    >> Share

    July 2022
  53. KATAYAMA A, Starczynski J, Toss MS, Shaaban AM, et al
    The frequency and clinical significance of centromere enumeration probe 17 alterations in HER2 immunohistochemistry-equivocal invasive breast cancer.
    Histopathology. 2022 Jul 25. doi: 10.1111/his.14728.
    >> Share

  54. RAKHA E, Tan PH
    Head to head: do neuroendocrine tumours in the breast truly exist?
    Histopathology. 2022;81:2-14.
    >> Share

    February 2022
  55. KATAYAMA A, Toss MS, Parkin M, Sano T, et al
    Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance.
    Histopathology. 2022;80:515-528.
    >> Share

  56. ABRAHAO-MACHADO LF, Bacchi CE, de Freitas CP, Hornick JL, et al
    Malignant peripheral nerve sheath tumour with multilineage divergent differentiation including a neuroblastic component.
    Histopathology. 2022;80:607-609.
    >> Share

    January 2022
  57. KHOURY T, Quinn M, Tian W, Yan L, et al
    Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.
    Histopathology. 2022;80:291-303.
    >> Share

    December 2021
  58. LI J, Mi W, Guo Y, Ren X, et al
    Artificial intelligence for histological subtype classification of breast cancer: combining multi-scale feature maps and recurrent attention model.
    Histopathology. 2021 Dec 24. doi: 10.1111/his.14613.
    >> Share

  59. MA S, Zhao D, Liu Y, Rohr J, et al
    Some pleomorphic adenomas of the breast share PLAG1 rearrangements with the analogous tumour of the salivary glands.
    Histopathology. 2021;79:1030-1039.
    >> Share

    November 2021
  60. KLARIC KA, Riaz N, Asleh K, Wang XQ, et al
    SOX10 is a highly specific biomarker of basal-like breast cancer.
    Histopathology. 2021 Nov 1. doi: 10.1111/his.14592.
    >> Share

    October 2021
  61. RAKHA E, Mihai R, Abbas A, Bennett R, et al
    Diagnostic concordance of phyllodes tumour of the breast.
    Histopathology. 2021;79:607-618.
    >> Share

  62. CAI L, Yan K, Bu H, Yue M, et al
    Improving Ki67 assessment concordance by the use of an artificial intelligence-empowered microscope: a multi-institutional ring study.
    Histopathology. 2021;79:544-555.
    >> Share

  63. RAKHA E, Tan PH, Ellis I, Quinn C, et al
    Adenomyoepithelioma of the breast: a proposal for classification.
    Histopathology. 2021;79:465-479.
    >> Share

    August 2021
  64. MANSY M, Wotherspoon AC, El-Sharkawi D, Cunningham D, et al
    Fibrin-associated diffuse large B-cell lymphoma misdiagnosed as breast implant-associated anaplastic large-cell lymphoma.
    Histopathology. 2021;79:269-271.
    >> Share

  65. BODEN ACS, Molin J, Garvin S, West RA, et al
    The human-in-the-loop: an evaluation of pathologists' interaction with artificial intelligence in clinical practice.
    Histopathology. 2021;79:210-218.
    >> Share

    May 2021
  66. MIHAI R, Callagy G, Qassid OL, Loughlin MO, et al
    Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast.
    Histopathology. 2021;78:871-881.
    >> Share

    April 2021
  67. RAKHA EA, Quinn CM, Foschini MP, Munoz Martin M, et al
    Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management.
    Histopathology. 2021;78:759-771.
    >> Share

    March 2021
  68. NOSKE A, Ammann JU, Wagner DC, Denkert C, et al
    A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Histopathology. 2021;78:567-577.
    >> Share

  69. GHOSSEIN CA, Khimraj A, Dogan S, Xu B, et al
    Metastasis to the thyroid gland: a single-institution 16-year experience.
    Histopathology. 2021;78:508-519.
    >> Share

  70. HODA RS, Bowman AS, Zehir A, Razavi P, et al
    Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 te
    Histopathology. 2021;78:498-507.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016